Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

Simona Pagliuca 1,2,3, Carmelo Gurnari 1,4, Colin Hercus 5, Sébastien Hergalant 6, Sanghee Hong 7, Adele Dhuyser 3,8, Maud D'Aveni 2,3, Alice Aarnink 3,8, Marie Thérèse Rubio 2,3, Pierre Feugier 2, Francesca Ferraro 9, Hetty E Carraway 10, Ronald Sobecks 11, Betty K Hamilton 11, Navneet S Majhail 12, Valeria Visconte 1, Jaroslaw P Maciejewski 13; 1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 2 Department of Hematology, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 3 CNRS UMR 7365, IMoPA, Biopole of University of Lorraine, Vandœuvre-lès-Nancy, France. 4 Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. 5 Novocraft Technologies Sdn Bhd, Kuala Lumpur, Malaysia. 6 Inserm UMR-S 1256 Nutrition-Genetics-Environmental Risk Exposure, University of Lorraine, 54500, Vandœuvre-lès-Nancy, France. 7 Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 8 Histocompatibility Department, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 9 Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. 10 Leukemia Program, Hematology Department, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 11 Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 12 Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA. 13 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.